JG
ACAD icon

Jefferies Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Jefferies Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-50,000
Closed -$705K – 1612
2022
Q2 		$705K Buy
+50,000
New +$933K 0.01% 894
2021
Q2 		– Sell
-52,900
Closed -$1.36M – 1625
2021
Q1 		$1.36M Buy
52,900
+1,300
+3% +$57.2K 0.01% 798
2020
Q4 		$2.76M Buy
51,600
+48,100
+1,374% +$2.39M 0.02% 613
2020
Q3 		$144K Hold
3,500
– – ﹤0.01% 1210
2020
Q2 		$170 Hold
3,500
– – ﹤0.01% 1078
2020
Q1 		$145K Buy
+3,500
New +$144K ﹤0.01% 1733
2018
Q4 		– Sell
-45,000
Closed -$934K – 2116
2018
Q3 		$934K Buy
+45,000
New +$708K 0.01% 1359
2018
Q1 		– Sell
-132,300
Closed -$3.98M – 2193
2017
Q4 		$3.98M Sell
132,300
-88,200
-40% -$2.82M 0.02% 649
2017
Q3 		$8.31M Buy
220,500
+121,500
+123% +$3.95M 0.05% 340
2017
Q2 		$2.76M Sell
99,000
-202,000
-67% -$6.02M 0.02% 799
2017
Q1 		$10.3M Buy
301,000
+284,800
+1,758% +$10.1M 0.08% 252
2016
Q4 		$467K Hold
16,200
– – ﹤0.01% 1617
2016
Q3 		$515K Sell
16,200
-4,000
-20% -$136K ﹤0.01% 1613
2016
Q2 		$656K Sell
20,200
-54,900
-73% -$1.84M ﹤0.01% 1309
2016
Q1 		$2.1M Buy
75,100
+55,100
+276% +$1.2M 0.01% 818
2015
Q4 		$713K Buy
20,000
+12,000
+150% +$423K ﹤0.01% 1337
2015
Q3 		$265K Hold
8,000
– – ﹤0.01% 1821
2015
Q2 		$335K Buy
+8,000
New +$310K ﹤0.01% 1736
2014
Q1 		– Sell
-15,000
Closed -$375K – 1990
2013
Q4 		$375K Hold
15,000
– – ﹤0.01% 1273
2013
Q3 		$412K Hold
15,000
– – ﹤0.01% 1286
2013
Q2 		$272K Buy
+15,000
New +$207K ﹤0.01% 1365

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jefferies Group's ACAD Position: Q3 2022 in Review

Jefferies Group sold out of Acadia Pharmaceuticals (ACAD) in Q3 2022, closing a stake of 48,424 shares — an estimated $682K sold.

Jefferies Group first reported a position in ACAD in Q2 2013 and held it in 27 quarters. The position peaked at $4.02M in Q3 2017. 222 funds tracked by Wall St. Rank hold ACAD as of Q3 2022.

  • Jefferies Group reported no remaining Acadia Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Jefferies Group sold 48,424 Acadia Pharmaceuticals shares in Q3 2022, an estimated $682K.
  • Jefferies Group first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 27 quarters.
  • Jefferies Group's Acadia Pharmaceuticals position peaked at $4.02M in Q3 2017.
  • 222 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.